Summary
Eli Lilly & Company (LLY) reported its second-quarter and first-half results for 2002, showing a decline in net sales and net income compared to the prior year. This downturn was largely attributed to the impact of generic competition for its key product, Prozac, which entered the U.S. market in August 2001. Despite the overall sales decrease, Lilly highlighted the strong growth of its "growth products" including Zyprexa, Humalog, Evista, Gemzar, Actos, and Xigris, which collectively showed a significant increase. The company also noted a reduction in research and development expenses, primarily due to lower late-stage clinical trial costs and incentive compensation, while marketing and administrative expenses saw a slight increase reflecting global sales force expansion. Financially, Lilly maintained a strong liquidity position with increased cash and cash equivalents, supported by operating cash flow and long-term debt issuance. However, the company faces ongoing regulatory scrutiny regarding its manufacturing practices, particularly at its Indianapolis facilities. The resolution of these manufacturing issues is critical for the approval of new products like Zyprexa IntraMuscular, Forteo, and Cymbalta. Despite these challenges, Lilly provided an earnings per share outlook for the third quarter and full year 2002, anticipating continued growth in 2003, though the precise timing of new product launches remains uncertain.
Key Highlights
- 1Net sales for the second quarter of 2002 decreased by 9% to $2.78 billion, and for the first six months by 9% to $5.34 billion, primarily due to the impact of generic fluoxetine (Prozac).
- 2Excluding Prozac, worldwide sales increased by 11% for the quarter and 10% for the six-month period, demonstrating growth in other product lines.
- 3Zyprexa sales showed strong growth, increasing 23% in the quarter and 26% for the six-month period, reaching $906.8 million and $1.73 billion, respectively.
- 4Net income for the second quarter decreased by 20% to $658.5 million ($0.61 per share), and for the first six months by 21% to $1.29 billion ($1.18 per share), impacted by the decline in Prozac sales and increased selling and marketing expenses.
- 5Research and development expenses decreased by 3% for the quarter and 4% for the six-month period, attributed to lower incentive compensation and late-stage trial costs.
- 6The company is implementing comprehensive improvements in its manufacturing operations in response to FDA observations and a warning letter, which could impact the approval timeline of new products.
- 7Lilly provided an updated financial outlook, expecting full-year 2002 earnings per share between $2.60 and $2.62, and forecasting earnings growth for 2003, contingent on the resolution of manufacturing issues and product launch success.